

Pfizer Oncology Sponsored Abstracts
2026 European Society for Medical Oncology (ESMO) Congress

Key:
Proffered Paper Session
Rapid Oral Presentation
Poster Presentation
ePoster

Lung			
Pfizer Asset	Presentation Number / Abstract Title	Type	Date / Time
Sigvotatug vedotin	LBA68 Phase 3 study of sigvotatug vedotin (SV) vs docetaxel in previously treated nonsquamous non-small cell lung cancer (NSCLC) [LBA]	Proffered Paper Session	October 25, 2026 10:15 – 11:45 CET
Fetrastobart vedotin	131P Prospective validation of artificial intelligence (AI)–assisted RECIST 1.1 in a phase 1 study of fetrastobart vedotin in patients with non–small cell lung cancer (NSCLC)	Poster Presentation	October 25, 2026 12:00 – 12:45 CET
Early Stage Development	320P A Comprehensive AI-Enabled Pre-Screening Panel for Non-Small Cell Lung Carcinoma (NSCLC) Using Computational Pathology Applied to H&E Whole Slide Images (WSI)	Poster Presentation	October 25, 2026 12:00 – 12:45 CET
Tivunatamig	2660P Phase 2 trial of the PD-1/VEGF bispecific antibody, PF-08634404 (SSGJ-707), plus chemotherapy (chemo) in advanced NSCLC: updated results [3SBio]	Poster Presentation	October 26, 2026 12:00 – 12:45 CET
Lorlatinib	2636P Characterizing resistance mechanisms and predictors of early progression and long-term response to lorlatinib: circulating tumor DNA (ctDNA) analyses from the CROWN study	Poster Presentation	October 26, 2026 12:00 – 12:45 CET
Lorlatinib	2676P Updated real-world outcomes with first-line lorlatinib in ALK-positive advanced NSCLC in Japan: ROYAL study second interim analysis	Poster Presentation	October 26, 2026 12:00 – 12:45 CET
Lorlatinib	2835eP Real-World Treatment Patterns and Performance Status Among Patients Receiving First-Line Lorlatinib in the United States	ePoster	N/A
Breast			
Pfizer Asset	Presentation Number / Abstract Title	Type	Date / Time
Atirmociclib	1842O Efficacy and safety of atirmociclib (ATI) + fulvestrant (FUL) in patients (pts) with	Proffered Paper Session	October 24, 2026 08:30 – 10:00 CEST

	HR+/HER2– advanced/metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitor (CDK4/6i) in a randomized phase 2 study (FOURLIGHT-1)		
Tucatinib	1766RO Health-Related Quality of Life from HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as 1L Maintenance Therapy for HER2+ mBC	Rapid Oral Session	October 24, 2026 10:15 – 11:45 CEST
Prifetrastat	1860P Phase 1/2a trial of prifetrastat in combination with vepdegestrant in patients (pts) with ER+/HER2– advanced/metastatic breast cancer (ABC): Results from dose escalation	Poster Presentation	October 24, 2026 12:00 – 12:45 CEST
Palbociclib	14P Long-term real-world overall survival with first-line palbociclib + aromatase inhibitor (AI) vs AI alone in HR+/HER2– metastatic breast cancer: a 10-year retrospective US study	Poster Presentation	October 24, 2026 12:00 – 12:45 CEST
Palbociclib	1790P Real world outcomes of maintenance modalities in first line HER2+ metastatic breast cancer: data from the ESME French cohort	Poster Presentation	October 24, 2026 12:00 – 12:45 CEST
Tucatinib	1815eP Beyond one-size-fits-all, new first-line (1L) HER2+ advanced breast cancer (aBC) therapies enable choice: A systematic literature review (SLR)	ePoster	N/A
Palbociclib	71eP Patient-reported health-related quality of life (HRQoL) with extended palbociclib use (≥3 years) in HR+/HER2- metastatic breast cancer (mBC), interim analysis (IA) from a global non-interventional study (NIS)	ePoster	N/A
Palbociclib	66eP Exploring patient experiences in metastatic breast cancer (mBC): Interviews to guide a global study	ePoster	N/A
Genitourinary: Bladder			
Pfizer Asset	Presentation Number / Abstract Title	Type	Date / Time
Enfortumab vedotin	4733O Perioperative pembrolizumab (pembro) or enfortumab vedotin (EV) plus pembro in pts with muscle-invasive bladder cancer (MIBC) who are cisplatin-ineligible: ad hoc analysis from KEYNOTE-905 [MSD led]	Proffered Paper Session	October 23, 2026 13:30 – 15:00 CEST
Enfortumab vedotin	4734O	Proffered Paper Session	October 23, 2026 13:30 – 15:00 CEST

	ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin [MSD led]		
Enfortumab vedotin	4738RO Health-related quality of life (HRQoL) with neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) plus pembrolizumab (pembro) in participants (pts) with muscle-invasive bladder cancer (MIBC) eligible for cisplatin in the phase 3 KEYNOTE-B15 study [MSD led]	Rapid Oral Session	October 24, 2026 10:15 – 11:45 CEST
Enfortumab vedotin	4740RO Enfortumab Vedotin (EV) With or Without Pembrolizumab (P) as First-Line (1L) Treatment for Cisplatin (cis)-Ineligible Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Long-Term Follow-Up Analysis From EV-103 Cohorts DE/A and K	Rapid Oral Session	October 24, 2026 10:15 – 11:45 CEST
Enfortumab vedotin	4760P Enfortumab Vedotin (EV) + Pembrolizumab (P) in Previously Untreated Locally Advanced or Metastatic Urothelial Cancer (la/mUC): Exploratory Analyses Based on Disease-Related Characteristics from EV-302	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Enfortumab vedotin	4761P Enfortumab Vedotin Plus Pembrolizumab (EV+P) For Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma (la/mUC): Updated Exploratory Analysis of EV-302 in Older Patients (pts) and Those With Comorbidities	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Enfortumab vedotin	4769TiP EV-209: An Open-label, Single-Arm, Phase 2 Study of Enfortumab Vedotin plus Pembrolizumab (EV+P) for Bladder Preservation in Patients with Muscle-invasive Bladder Cancer (MIBC) Eligible for Radical Cystectomy (RC) [TiP] [Astellas led]	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Enfortumab vedotin	4770TiP EV-309: An Open-Label, Randomized Phase 3 Study of Enfortumab Vedotin plus Pembrolizumab (EV+P) for Bladder Preservation in Patients (pts) with Muscle-invasive Bladder Cancer (MIBC) [TiP]	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Enfortumab vedotin	4833eP	ePoster	N/A

	Real-world (RW) treatment (tx) patterns in patients (pts) with locally advanced and metastatic urothelial cancer (la/mUC) in France [Astellas led]		
Genitourinary: Prostate			
Pfizer Asset	Presentation Number / Abstract Title	Type	Date / Time
Talazoparib	2219RO Utility of ctDNA tumor fraction (TF) as a prognostic biomarker in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in patients (pts) with homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)	Rapid Oral Session	October 23, 2026 13:30 – 15:00 CEST
Talazoparib	2222RO Patient-reported outcomes (PROs) in men with metastatic castration-sensitive prostate cancer (mCSPC) and homologous recombination repair (HRR) gene alterations receiving talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA: Results from the Phase 3 TALAPRO-3 study	Rapid Oral Session	October 23, 2026 13:30 – 15:00 CEST
Talazoparib	2231P Talazoparib (TALA) + enzalutamide (ENZA) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations: safety analyses from the Phase 3 TALAPRO-3 study	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Enzalutamide	2293P Deep prostate-specific antigen (P5A) response by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR): EMBARK post hoc analysis	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Enzalutamide	2294P Indirect safety comparison of enzalutamide (ENZA) and darolutamide (DARO) with androgen-deprivation therapy (ADT) in metastatic hormone-sensitive prostate cancer (mHSPC)	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Enzalutamide	2295P Network meta-analysis (NMA) on the safety of androgen receptor pathway inhibitors (ARPIs) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from German AMNOG dossiers	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Mevrometostat	2296P Safety and efficacy of mevrometostat monotherapy in patients (pts) with	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST

	metastatic castration-resistant prostate cancer (mCRPC)		
Talazoparib	2263P Prostate-specific antigen (PSA) endpoints with exploratory gene by gene subgroups in homologous recombination repair (HRR) gene–altered metastatic castration sensitive prostate cancer (mCSPC) from TALAPRO-3	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Talazoparib	2229P Prognostic utility of circulating tumor cell (CTC) count, CTC conversion, and CTC0 in TALAPRO-3: Phase 3 study of talazoparib (TALA) + enzalutamide (ENZA) vs placebo (PBO) + ENZA in homologous recombination repair (HRR) gene–mutated metastatic castration-sensitive prostate cancer (mCSPC)	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Talazoparib	2241P Biomarker analysis in the China cohort of the Phase 3 TALAPRO-2 trial of first-line talazoparib (TALA) with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC)	Poster Presentation	October 23, 2026 15:15 – 16:00 CEST
Enzalutamide	2063eP High-risk biochemically recurrent (hrBCR) hormone sensitive prostate cancer (PC): European real-world (RW) evidence on risk stratification, PSMA PET use, and physician practices	ePoster	N/A
Enzalutamide	2329eP Outcomes of enzalutamide (ENZ) and apalutamide (APA) in metastatic hormone-sensitive prostate cancer (mHSPC): a Canadian real-world (RW) study	ePoster	N/A
Mevrometostat	2355eP Real-world patterns of androgen receptor pathway inhibitor (ARPI) rechallenge in first-line (1 L) metastatic castration-resistant prostate cancer (mCRPC)	ePoster	N/A
Mevrometostat	2360eP Recent US real-world (rw) utilization of androgen receptor pathway inhibitor (ARPI) rechallenge in first-line (1 L) metastatic castration resistant prostate cancer (mCRPC)	ePoster	N/A
Mevrometostat	2362eP Treatment (tx) patterns and decision drivers in first-line (1L) metastatic castration-resistant prostate cancer (mCRPC) following prior androgen receptor pathway inhibitor (ARPI) exposure; analysis from a global real-world survey	ePoster	N/A

Melanoma			
Pfizer Asset	Presentation Number / Abstract Title	Type	Date / Time
Enco/Bini (CRC, Mel)	2071O STARBOARD Phase 3: A randomized, double-blind study of first-line (1L) encorafenib (enco), binimetinib (bini), and pembrolizumab (pembro) vs placebo (pbo) and pembro for unresectable locally advanced or metastatic BRAF V600-mutant melanoma	Proffered Paper Session	October 23, 2026 16:15 – 17:45 CEST
Genitourinary: Kidney			
Pfizer Asset	Presentation Number / Abstract Title	Type	Date / Time
Tivunatamig	3710eTiP Symbiotic-GU-08: Phase 1b/2 study of PF-08634404, a PD-1/VEGF bispecific antibody, with or without other anticancer agents in patients (pts) with locally advanced or metastatic renal cell carcinoma (la/mRCC) [TiP]	ePoster	N/A
Gastrointestinal (GI)			
Pfizer Asset	Presentation Number / Abstract Title	Type	Date / Time
General	968eP Survival Outcomes in Metastatic Colorectal Cancer: An analysis of the US population-based SEER database	ePoster	N/A
Gynecological Cancers			
Pfizer Asset	Presentation Number / Abstract Title	Type	Date / Time
Tivunatamig	1337TiP Symbiotic-GYN-18 (APGOT-EN6/GOG-3145/ENGOT-EN37): Phase 3 study of PF-08634404, a PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients (pts) with advanced or recurrent mismatch repair proficient (pMMR) endometrial cancer (EC) [TiP]	Poster Presentation	October 26, 2026 12:00 – 12:45 CET